Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Reporting Period: Fiscal year ended December 31, 2024
Corporate Status: Clinical-stage biopharmaceutical company spun off from Inhibrx, Inc. (Former Parent) in May 2024. The Former Parent merged with Aventis Inc. (a Sanofi subsidiary), transferring the INBRX-101 program to Sanofi. Inhibrx Biosciences retained the INBRX-106 and ozekibart (INBRX-109) oncology programs.
Key Developments: The company became a standalone public entity on May 30, 2024. In January 2025, it secured a new $100 million term loan facility from Oxford Finance LLC.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0.2 million | $1.8 million |
| Net Income (Loss) | $1,687.6 million | ($241.4 million) |
| Operating Loss | ($331.4 million) | ($219.2 million) |
| Cash and Cash Equivalents (Year End) | $152.6 million | $277.9 million |
| Accumulated Deficit | ($106.1 million) | ($613.7 million) |
| Debt Outstanding | $0 (Assumed by Acquirer) | $207.0 million |
Note: The 2024 Net Income is driven by a non-cash gain of $2.0 billion related to the transaction with the Acquirer (Sanofi/Aventis). Operating cash flow remains negative at $194.4 million used in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 89% to $0.2 million, primarily due to the cessation of revenue from the Phylaxis BioScience agreement in 2024 compared to 2023.
- Operating Expenses: Total operating expenses increased 50% to $331.6 million. General and Administrative (G&A) expenses surged 335% to $127.9 million, largely due to $68.1 million in one-time merger-related costs and accelerated stock-based compensation.
- Debt Extinguishment: The company's previous $200 million debt obligation was assumed by the Acquirer in the May 2024 merger, resulting in a $211.3 million gain on extinguishment.
- Stock-Based Compensation: Total stock-based compensation expense was $58.5 million in 2024, significantly higher than 2023 due to the acceleration of options upon the merger.
Guidance, Outlook, and Risks
Clinical Pipeline and Milestones
- ozekibart (INBRX-109): A tetravalent DR5 agonist. Phase 2 data for chondrosarcoma is expected in Q3 2025. Interim data for Ewing sarcoma and colorectal cancer cohorts are anticipated in H2 2025 and Q3 2025, respectively.
- INBRX-106: A hexavalent OX40 agonist. Phase 2 data for head and neck squamous cell carcinoma (HNSCC) is expected in Q4 2025. A seamless Phase 2/3 trial was initiated in June 2024.
Liquidity and Capital Resources
As of December 31, 2024, the company held $152.6 million in cash. Management believes this is sufficient to fund operations for at least 12 months. In January 2025, the company entered a new loan agreement providing $100 million in immediate funding with an option for an additional $50 million.
Risks and Contingencies
- Regulatory Risks: The Phase 2 trial for ozekibart was previously placed on partial clinical hold in 2023 due to hepatotoxicity; the hold was lifted in April 2023 after protocol amendments.
- Financial Risks: The company has a history of significant operating losses and expects to continue incurring losses until product approval. Future funding may require dilution or restrictive debt covenants.
- Legal: A trade secrets case brought by I-Mab Biopharma was settled in January 2025 with the action dismissed with prejudice.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $152.6 million cash balance plus the new $100 million loan against the projected burn rate for 2025 clinical trials.
- Merger Accounting: Confirm the non-recurring nature of the $2.0 billion gain and its impact on the reported net income versus operating performance.
- Clinical Safety: Monitor upcoming data readouts for ozekibart (INBRX-109) to ensure the hepatotoxicity risks identified in 2023 remain mitigated in the expanded cohorts.
- Debt Covenants: Review the terms of the January 2025 Oxford Loan Agreement for restrictive covenants that may limit future operational flexibility.
- Revenue Sustainability: Assess the likelihood of future revenue streams given the cessation of the Phylaxis milestone revenue and the small license fee revenue from Regeneron.